Nutex Health (NUTX) Stock Price, News & Analysis

Company Overview

Nutex Health Inc. operates as a physician-led, healthcare services, and operations company. It operates through three segments: Hospital, Population Health Management (PHM), and Real Estate. The PHM segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment owns and owns and leases land and hospital building. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. It also provides operational and managerial services, including management, billing, collections, human resources and recruiting, legal, accounting, and marketing. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.

Key Stats

• Today's Range: $155.01 to $177.50
• 50-Day Range: $45.68 to $174.71
• 52-Week Range: $4.16 to $182.00
• Volume: 214,430 shs
• Average Volume: 66,065 shs
• Market Capitalization: $965.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $200.00
• Consensus Rating: Buy

Nutex Health Stock Analysis - MarketRank™

Nutex Health scored higher than 37% of companies evaluated by MarketBeat, and ranked 700th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nutex Health has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nutex Health has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nutex Health is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nutex Health is -18.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nutex Health has a P/B Ratio of 9.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.36% of the float of Nutex Health has been sold short.

Short Interest Ratio / Days to Cover

Nutex Health has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nutex Health has recently increased by 13.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nutex Health does not currently pay a dividend.

Dividend Growth

Nutex Health does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.36% of the float of Nutex Health has been sold short.

Short Interest Ratio / Days to Cover

Nutex Health has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nutex Health has recently increased by 13.05%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.76

News Sentiment

Nutex Health has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Nutex Health this week, compared to 2 articles on an average week.

Search Interest

Only 8 people have searched for NUTX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

4 people have added Nutex Health to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Nutex Health insiders have bought more of their company's stock than they have sold. Specifically, they have bought $81,810.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

38.52% of the stock of Nutex Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 5.32% of the stock of Nutex Health is held by institutions.

NUTX Stock Analysis - Frequently Asked Questions

How have NUTX shares performed this year?

Nutex Health's stock was trading at $31.69 on January 1st, 2025. Since then, NUTX stock has increased by 451.3% and is now trading at $174.71.
View the best growth stocks for 2025 here.

How were Nutex Health's earnings last quarter?

Nutex Health Inc. (NASDAQ:NUTX) announced its quarterly earnings data on Tuesday, May, 13th. The company reported $2.56 EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $2.71. The business had revenue of $211.79 million for the quarter, compared to analysts' expectations of $81.09 million. Nutex Health had a negative trailing twelve-month return on equity of 51.27% and a negative net margin of 14.09%.
Read the conference call transcript.

When did Nutex Health's stock split?

Nutex Health shares reverse split before market open on Wednesday, July 3rd 2024. The 1-10 reverse split was announced on Wednesday, July 3rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 3rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Nutex Health's major shareholders?

Nutex Health's top institutional shareholders include Topline Capital Management LLC (3.25%), Essex Investment Management Co. LLC (1.58%), American Century Companies Inc. (1.35%) and Legato Capital Management LLC (0.47%). Insiders that own company stock include Thomas T Vo, Jon Christian Bates, Joshua Detillio, John J Waters, Pamela W Montgomery and Michael Lee Reed.
View institutional ownership trends.

How do I buy shares of Nutex Health?

Shares of NUTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nutex Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nutex Health investors own include Predictive Oncology (POAI), Ford Motor (F), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Cricut (CRCT).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 5/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Business services, not elsewhere classified
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:NUTX
• CIK: 1479681
• Web: www.nutexhealth.com
• Phone: (713) 660-0557
• Fax: 631-670-6780
• Employees: 1,150
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $200.00
• High Stock Price Target: $300.00
• Low Stock Price Target: $100.00
• Potential Upside/Downside: +14.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $11.89
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-45,790,000.00
• Net Margins: -14.09%
• Pretax Margin: -10.12%
• Return on Equity: -51.27%
• Return on Assets: -9.89%

Debt

• Debt-to-Equity Ratio: 3.36
• Current Ratio: 1.77
• Quick Ratio: 1.74

Sales & Book Value

• Annual Sales: $479.95 million
• Price / Sales: 2.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $17.68 per share
• Price / Book: 9.88

Miscellaneous

• Outstanding Shares: 5,528,000
• Free Float: 3,343,000
• Market Cap: $965.80 million
• Optionable: Not Optionable
• Beta: -0.10